CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has ruled in favor of the Appellants in oral proceedings before the Board of Appeals related to the ’623 (EP 1144623) patent in its Kreutzer-Limmer patent estate. This ruling does not affect other granted claims of the Kreutzer-Limmer patent series, nor does it affect the ongoing examination of other applications, which the company expects will result in new granted patents. Alnylam also announced today that the EPO intends to grant a new patent from the Kreutzer-Limmer patent family, EP 1550719, or ’719, which covers siRNAs comprising 15-21 nucleotides in length stabilized by chemical linkages.
